CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Cytox has developed the variaTECT platform, which assesses the risk of Alzheimer's Disease using genetic information from blood or saliva samples. This cost-effective method aims to improve early diagnosis and stratification of individuals at risk.
Alzheimer’s Disease (AD) is the most prevalent cognitive disorder and progressively leads to complete brain dysfunction anddegeneration.
The number of people living with Alzheimer’s worldwide is now estimated at 46M, with this figure set to almostdouble by 2030 and more than triple by 2050 due to population aging.
Current methods for early assessment of AD arebased on detection of β-amyloid in the brain Positron Emission Tomography (PET) scans, blood plasma tests or incerebrospinal fluid (CSF) (…
CYTOX LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
